Liver/Biliary Disorders News

Larsucosteral was well-tolerated and improved short-term biomarkers of liver injury or disease in a subset of patients with moderate to severe alcohol-associated hepatitis, according to research in The American Journal of Gastroenterology.

April is Alcohol Awareness Month, an annual campaign originally created to raise awareness about alcoholism and the impacts of alcohol on health — and a month-long opportunity to open a dialogue on the topic with patients.

Bariatric surgery was linked to a decreased risk for major adverse cardiovascular events and all-cause mortality among patients with nonalcoholic fatty liver disease and obesity, according to results in JAMA Network Open.

Metabolic comorbidities heightened risk for adverse liver-related events among patients with chronic hepatitis B virus, with the highest risk found among patients with multiple comorbidities, according to research.

The prevalence of nonalcoholic fatty liver disease was 14% among pregnant women screened during early pregnancy, with fewer than 5% receiving prior evaluation for NAFLD, according to research in Clinical Gastroenterology and Hepatology.

A machine learning model using artificial neural networks demonstrated “superior performance” compared with MELD score for predicting 28-day mortality among patients with hepatic encephalopathy, according to data in BMC Gastroenterology.

Infection with SARS-CoV-2 increased the risk for long-term gastrointestinal problems within 1 year, including motility disorders, acute pancreatitis and liver disease, according to a study published in Nature Communications.

Although Black individuals with chronic hepatitis B were less likely to meet treatment criteria, researchers reported no significant differences in treatment initiation between racial groups, according to data in JAMA Network Open.

Liver transplant candidates with a small stature experienced longer waitlist times and had lower rates of transplant, with the smallest 25% of candidates most affected, according to study results in JAMA Surgery.

Arrowhead Pharmaceuticals announced that the first patient has been treated in Takeda Pharmaceuticals’ phase 3 clinical trial of fazirsiran for the treatment of alpha-1 antitrypsin deficiency associated liver disease.